Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Paratek Pharmaceuticals revenue
Paratek Pharmaceuticals's revenue is $160.3 million.
What is Paratek Pharmaceuticals's revenue?
- Paratek Pharmaceuticals's revenue growth from 2005 to 2022 is 286,092.86%.
- Paratek Pharmaceuticals has 208 employees, and the revenue per employee ratio is $770,519.
- Paratek Pharmaceuticals's peak quarterly revenue was $75.6M in 2022(q4).
- Paratek Pharmaceuticals peak revenue was $160.3M in 2022.
- Paratek Pharmaceuticals annual revenue for 2021 was 130.2M, 177.39% growth from 2020.
- Paratek Pharmaceuticals annual revenue for 2022 was 160.3M, 23.13% growth from 2021.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Paratek Pharmaceuticals historical revenue
Paratek Pharmaceuticals's peak revenue was $160.3M in 2022. The peak quarterly revenue was $75.6M in 2022(q4).
Paratek Pharmaceuticals's revenue increased from $56.0k in 2005 to $160.3M currently. That's a 286,092.86% change in annual revenue.
Paratek Pharmaceuticals annual revenue
Paratek Pharmaceuticals annual revenue over time
| Fiscal year / year | Paratek Pharmaceuticals revenue |
|---|---|
| 2009 | $5.2M |
| 2010 | $12.5M |
| 2011 | $19.7M |
| 2012 | $11.0M |
| 2014 | $4.3M |
| 2016 | $29,000 |
| 2017 | $12.6M |
| 2018 | $17.1M |
| 2019 | $16.5M |
| 2020 | $46.9M |
| 2021 | $130.2M |
| 2022 | $160.3M |
Rate Paratek Pharmaceuticals' financial transparency
Paratek Pharmaceuticals annual growth
Paratek Pharmaceuticals saw the greatest revenue growth in 2017, when revenue increased by 43,403.45%.
Paratek Pharmaceuticals had the lowest revenue growth in 2016, when revenue changed by -99.33%.
Paratek Pharmaceuticals annual growth rate over time
| Year | Paratek Pharmaceuticals growth |
|---|---|
| 2009 | 1304%↑ |
| 2010 | 140%↑ |
| 2011 | 58%↑ |
| 2012 | -44%↓ |
| 2014 | -61%↓ |
| 2016 | -99%↓ |
| 2017 | 43403%↑ |
| 2018 | 36%↑ |
| 2019 | -3%↓ |
| 2020 | 184%↑ |
| 2021 | 177%↑ |
| 2022 | 23%↑ |
Paratek Pharmaceuticals quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Paratek Pharmaceuticals quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2009 | - | - | $2.1M | $3.1M |
| 2010 | $3.1M | $3.1M | $3.1M | $3.1M |
| 2011 | $3.1M | $3.1M | $625,000 | $12.8M |
| 2012 | - | $493,000 | $10.4M | $93,000 |
| 2017 | $18,000 | $7.5M | $12,000 | $5.1M |
| 2018 | $10,000 | $40,000 | $50,000 | $17.0M |
| 2019 | $1.6M | $2.0M | $3.9M | $9.0M |
| 2020 | $7.9M | $9.3M | $13.7M | $16.0M |
| 2021 | $16.4M | $57.5M | $24.4M | $31.8M |
| 2022 | $24.9M | $29.6M | $30.2M | $75.6M |
| 2023 | $31.2M | $40.0M | - | - |
Paratek Pharmaceuticals jobs nearby
Do you work at Paratek Pharmaceuticals?
Is Paratek Pharmaceuticals transparent about its revenue structure?
Paratek Pharmaceuticals financial information
| CEO | Evan Loh M.d |
| Company Type | Public |
| Employees Number | 208 |
| Date Founded | 1996 |
| Headquarters | Boston, Massachusetts |
| Number of Locations | 2 |
| Revenue | $160.3M |
| Net Income | -$63,566,000 |
| Gross Proft | $137.2M (2022) |
| Tax Rate | -0.0% |
| Total Assets | $172,538,000 |
| Ticker | PRTK |
Paratek Pharmaceuticals jobs you might like
Paratek Pharmaceuticals financing
Paratek Pharmaceuticals received early financing of $40.0M on 2007-10-26.
| Series | Round size | Date |
|---|---|---|
| Post Ipo Equity | $40M | 10/2007 |
| Post Ipo Debt | $93M | 07/2014 |
Paratek Pharmaceuticals investors
| Investors | Security type |
|---|---|
| Pacific Growth Equities LLC | Post Ipo Equity |
| IBT Management Corporation | Post Ipo Equity |
| D.E. Shaw & Co. | Post Ipo Equity |
| Aisling Capital | Post Ipo Equity |
| Abingworth | Post Ipo Debt |
| Baupost Group | Post Ipo Debt |
| Omega Funds | Post Ipo Debt |
| Aisling Capital | Post Ipo Debt |
Paratek Pharmaceuticals competitors
Paratek Pharmaceuticals's top competitor, XORTX Therapeutics, earned an annual revenue of $6.2B.
Paratek Pharmaceuticals's smallest competitor is Sequoia Sciences with revenue of $260.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Tetraphase Pharmaceuticals | - | $7.4M | 67 | - |
| Akebia Therapeutics | - | $160.2M | 324 | - |
| Optimer Pharmaceuticals | - | $144.0M | 281 | - |
| Achaogen | - | $8.7M | 42 | - |
| XORTX Therapeutics | - | $6.2B | 2 | - |
| Spero Therapeutics | - | $48.0M | 41 | - |
| Trevi Therapeutics | - | $905.2M | 20 | - |
| Akari Therapeutics | - | $1.6M | 8 | - |
| Absorption Systems | - | $26.0M | 163 | - |
| SCYNEXIS | - | $3.7M | 24 | - |
Paratek Pharmaceuticals revenue FAQs
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Most in demand jobs
Zippia gives an in-depth look into the details of Paratek Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Paratek Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Paratek Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Paratek Pharmaceuticals. The data presented on this page does not represent the view of Paratek Pharmaceuticals and its employees or that of Zippia.
Paratek Pharmaceuticals may also be known as or be related to PARATEK PHARMACEUTICALS INC, Paratek Pharmaceuticals, Paratek Pharmaceuticals Inc and Paratek Pharmaceuticals, Inc.